Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Further evidence of the benefits of double auto-SCT

Michele Cavo • 17 May 2019
COMy 2019
Multiple Myeloma Bortezomib
EMN02

Here, Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses a retrospective analysis of three previous European trials which compared bortezomib-based vs. non-bortezomib based transplant regimens for multiple myeloma. This supported the EMN02 trial (NCT01208766) data, which suggested that double transplants provided more benefits than single transplants. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.

More from Michele Cavo

1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals